OnCo
ideasIdea

Oncolytic viruses that make interleukin-12 only inside the tumour

Interleukin-12 is one of the most powerful immune stimulants but is too toxic to inject into the bloodstream. A virus can be engineered to make it only inside a tumour.

Systemic interleukin-12 caused severe toxicity in the 1990s and was abandoned. Oncolytic herpes and adenovirus vectors carrying interleukin-12 under regulated or drug-inducible promoters, including trials in recurrent glioblastoma, keep exposure local and measurable. Combining a regulated cytokine payload with checkpoint blockade is a rational path to converting cold tumours.

Hypothesis
A regulated intratumoural interleukin-12 payload achieves tumour-to-plasma cytokine ratios above 100 and produces T-cell infiltration in previously cold lesions, without dose-limiting systemic toxicity.
Rationale
The failure of interleukin-12 was pharmacokinetic, not immunological, and local delivery is exactly the right fix. Oncolytic products are already approved in melanoma and bladder cancer, so the manufacturing and regulatory route exists.
What would test it
Dose-escalation with paired biopsies and matched plasma cytokine measurement, reporting tumour-to-plasma ratio and change in CD8 density as the primary endpoints, before efficacy expansion.
Maturity
early clinical
Who has to act
industry
Cost to try
Medium ($1M to $50M)
Years to first evidence
7
Bottlenecks it attacks

Connected

15top

Pages like this

not linked directly; found by shared links